Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

CYCC stock opened at $1.50 on Wednesday. Cyclacel Pharmaceuticals has a 12 month low of $1.41 and a 12 month high of $13.20. The company’s 50-day moving average price is $2.29 and its two-hundred day moving average price is $3.84.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.35) by $0.12. The company had revenue of $0.03 million for the quarter. On average, sell-side analysts expect that Cyclacel Pharmaceuticals will post -18.7 EPS for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.